PMID- 9305600
OWN - NLM
STAT- MEDLINE
DCOM- 19971016
LR  - 20240104
IS  - 0887-6924 (Print)
IS  - 0887-6924 (Linking)
VI  - 11
IP  - 9
DP  - 1997 Sep
TI  - Two acute monocytic leukemia (AML-M5a) cell lines (MOLM-13 and MOLM-14) with 
      interclonal phenotypic heterogeneity showing MLL-AF9 fusion resulting from an 
      occult chromosome insertion, ins(11;9)(q23;p22p23).
PG  - 1469-77
AB  - We describe two new human leukemia cell lines, MOLM-13 and MOLM-14, established 
      from the peripheral blood of a patient at relapse of acute monocytic leukemia, 
      FAB M5a, which had evolved from myelodysplastic syndrome (MDS). Both cell lines 
      express monocyte-specific esterase (MSE) and MLL-AF9 fusion mRNA. Gene fusion is 
      associated with a minute chromosomal insertion, ins(11;9)(q23;p22p23). MOLM-13 
      and MOLM-14 are the first cell lines with, and represent the third reported case 
      of, MLL gene rearrangement arising via chromosomal insertion. Both cell lines 
      carry trisomy 8 which was also present during the MDS phase, as well as the most 
      frequent trisomies associated with t(9;11), ie, +6, +13, +19 variously present in 
      different subclones. Despite having these features in common, differences in 
      antigen expression were noted between the two cell lines: that of MOLM-13 being 
      CD34+, CD13-, CD14-, CD15+, CD33+; whereas MOLM-14 was CD4+, CD13+, CD14+, CD15+, 
      CD33+. Differentiation to macrophage-like morphology could be induced in both 
      cell lines after stimulation with INF-gamma alone, or in combination with 
      TNF-alpha, which treatment also induced or upregulated, expression of certain 
      myelomonocyte-associated antigens, including CD13, CD14, CD15, CD64, CD65 and 
      CD87. Together, these data confirm that both cell lines are likely to be novel in 
      vitro models for studying monocytic differentiation and leukemogenesis.
FAU - Matsuo, Y
AU  - Matsuo Y
AD  - Fujisaki Cell Center, Hayashibara Biochemical Labs, Inc., Okayama, Japan.
FAU - MacLeod, R A
AU  - MacLeod RA
FAU - Uphoff, C C
AU  - Uphoff CC
FAU - Drexler, H G
AU  - Drexler HG
FAU - Nishizaki, C
AU  - Nishizaki C
FAU - Katayama, Y
AU  - Katayama Y
FAU - Kimura, G
AU  - Kimura G
FAU - Fujii, N
AU  - Fujii N
FAU - Omoto, E
AU  - Omoto E
FAU - Harada, M
AU  - Harada M
FAU - Orita, K
AU  - Orita K
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - England
TA  - Leukemia
JT  - Leukemia
JID - 8704895
RN  - 0 (Antigens, CD)
RN  - 0 (Cytokines)
RN  - 0 (DNA, Neoplasm)
RN  - 0 (DNA-Binding Proteins)
RN  - 0 (KMT2A protein, human)
RN  - 0 (MLLT3 protein, human)
RN  - 0 (Nuclear Proteins)
RN  - 0 (RNA, Messenger)
RN  - 0 (Transcription Factors)
RN  - 149025-06-9 (Myeloid-Lymphoid Leukemia Protein)
RN  - EC 2.1.1.43 (Histone-Lysine N-Methyltransferase)
SB  - IM
MH  - Adult
MH  - Antigens, CD/metabolism
MH  - Chromosome Aberrations/*genetics
MH  - Chromosome Banding
MH  - Chromosome Disorders
MH  - Chromosomes, Human, Pair 11
MH  - Chromosomes, Human, Pair 9
MH  - Cytokines/pharmacology
MH  - DNA, Neoplasm/*genetics
MH  - DNA-Binding Proteins/*genetics
MH  - Gene Expression Regulation, Neoplastic
MH  - Histone-Lysine N-Methyltransferase
MH  - Humans
MH  - Immunophenotyping
MH  - In Situ Hybridization, Fluorescence
MH  - Karyotyping
MH  - Leukemia, Monocytic, Acute/*genetics
MH  - Male
MH  - Myeloid-Lymphoid Leukemia Protein
MH  - Nuclear Proteins/*genetics
MH  - Phenotype
MH  - *Proto-Oncogenes
MH  - RNA, Messenger/genetics
MH  - *Transcription Factors
MH  - *Tumor Cells, Cultured
EDAT- 1997/09/26 00:00
MHDA- 1997/09/26 00:01
CRDT- 1997/09/26 00:00
PHST- 1997/09/26 00:00 [pubmed]
PHST- 1997/09/26 00:01 [medline]
PHST- 1997/09/26 00:00 [entrez]
AID - 10.1038/sj.leu.2400768 [doi]
PST - ppublish
SO  - Leukemia. 1997 Sep;11(9):1469-77. doi: 10.1038/sj.leu.2400768.